Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 1153 • ACR Convergence 2023
Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches
Manush Sondhi¹, Warda Maqsood² and Sarwat Umer³, ¹Louisiana State University, Shreveport, LA, ²LSU Health Science Center, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA
Background/Purpose: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a relatively rare and often underdiagnosed inflammatory disorder. Its diagnosis can be challenging due to its…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 1656 • ACR Convergence 2023
Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)
anna Fryxelius¹, Amy Martinsen², Ida Løchting³, Linda Aimee Hartford Kvæl⁴, Astrid Lunestad², Astrid Bergland⁴ and Kjersti Storheim², ¹Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, ⁴OsloMET, Oslo, Norway
Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
Abstract Number: 0252 • ACR Convergence 2023
Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort
Lindsay Pattison¹, Bibi Ayesha², Anand Kumthekar³, Maureen McEvoy², Beth McLellan² and Inessa Gendlina², ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Granulomatous mastitis (GM) is a rare, chronic, inflammatory breast condition characterized by granulomatous inflammation affecting mainly minority women of childbearing age. Patients present with…
Abstract Number: 1806 • ACR Convergence 2023
The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis
Daming Shao¹, Jiyoung Seo¹, Shaunak Mangeshkar¹, Natalia Nazarenko¹, Stepan Esagian¹, Leonidas Palaiodimos¹ and Damianos Kokkinidis², ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
Abstract Number: 0262 • ACR Convergence 2023
Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients
Xavier Puéchal¹, Philippe Blanche², Olivier Fogel³, Omar Al Tabaa⁴, Roba Ghossan⁴, Xavier Ayral⁴, Jerome AVOUAC⁵, Maxime Breban⁶ and Yannick ALLANORE⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Department of Rheumatology, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁶Department of Rheumatology, Boulogne-Billancourt, France, ⁷Université Paris Cité, Paris, France
Background/Purpose: Whipple disease is a chronic, curable, systemic bacterial infection caused by Tropheryma whipplei. The classic form usually begins with recurrent arthritis, followed years later…
Abstract Number: 1851 • ACR Convergence 2023
Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar
Chiara Gasteiger¹, Maria Lobo², Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is…
Abstract Number: 0263 • ACR Convergence 2023
Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease
Taylor Koenig¹, David Fell¹, Danny Mammo¹, Chao Zhang², Sunil Srivastava¹, Careen Lowder¹, Sumit Sharma¹ and Rula Hajj-Ali¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic…
Abstract Number: 1921 • ACR Convergence 2023
Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department
Herman Mann¹, Blanka Stiburkova², Katerina Pavelcova¹, Monika Belickova³, Cyril Salek³, Jana Juhaszova¹ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: VEXAS (vacuoles, E1 activating enzyme, X-linked, auto-inflammatory, somatic) syndrome is a clinically serious and potentially fatal adult-onset disease caused by somatic mutations in the…
Abstract Number: 0270 • ACR Convergence 2023
Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
Tomohiro Koga¹, Remi Sumiyoshi¹, Yoshika Tsuji¹, Ken Kodama², Kaori Furukawa¹, Yushiro Endo¹ and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ²Neophama Japan, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan
Background/Purpose: The primary objective of this study is to elucidate the therapeutic potential of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) in ameliorating the pathological manifestations associated…
Abstract Number: 1924 • ACR Convergence 2023
Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD
Caroline Siegel¹, Lucy Masto¹, Amaya Smole¹, Bessie Stamm¹, JoAnn Vega¹, Dongmei Sun¹, Deanna Jannat-Khah¹, Michael Lockshin², Lisa Sammaritano² and Medha Barbhaiya², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: The early COVID-19 pandemic led to physical and psychological burdens for patients with systemic rheumatic diseases, whether or not they had had COVID-19. To…
Abstract Number: 0272 • ACR Convergence 2023
Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Marion Peyre¹, Arthur Mageau¹, Marie-cecile Henry Feugeas², Serge Doan², Caroline Halimi², Isabelle Klein³, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³Clinique Alleray-Labrouste, Paris, France
Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 0281 • ACR Convergence 2023
Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?
Kristin Schmiedeberg¹, Anna-Lena Walter¹, Lukas Joos¹, Martin Brutsche¹, Johannes von Kempis² and Andrea Rubbert-Roth¹, ¹Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Tegveer Sandhu¹, Lea Meir², Nicole Ng¹, Lila Klein¹, Jigna Zatakia¹, Maria Padilla¹ and Ioannis Tassiulas¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine, New York, NY
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.